jRCT2031230317进行中（未招募）不适用
A phase III study (physician-initiated clinical trial) to evaluate the efficacy and safety of sirolimus for epileptic seizures with focal cortical dysplasia type II
未提供0 个研究点目标入组 20 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 20
- 主要终点
- Relative reduction in the frequency of epileptic seizures
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Double Blind
入排标准
- 年龄范围
- 1age old over 至 No limit（—）
- 性别
- All
入选标准
- •(1) Patients with a diagnosis of focal cortical dysplasia type II (including hemimegalencephaly) based on neuroimaging findings by head MRI within 156 weeks prior to enrollment or brain pathology prior to enrollment
- •(2) Patients aged 1 year or older at the time of consent
- •(3) Patients diagnosed with focal motor onset seizures (with motor signs which are able to be confirmed by others) or focal to bilateral tonic-clonic seizures associated with FCD based on the operational classification of seizure types by the International League Against Epilepsy (ILAE) 2017 (Appendix 1)
- •(4) Patients who have been treated with at least 2 antiepileptic drugs for at least 26 weeks since the diagnosis of epilepsy
- •(5) Patients on treatment with 1 to 4 antiepileptic drugs at the time of consent
- •(6) Patients whose dosage and administration of antiepileptic drugs has been constant for 8 weeks prior to enrollment
- •(7) Patients whose vagal nerve stiumulation therapy stimulation conditions have been constant for 8 weeks prior to enrollment
- •(8) Patients with at least 2 focal motor onset seizures (with motor signs which are able to be confirmed by others) or focal to bilateral tonic-clonic seizures during the 28-day baseline observation period
- •(9) Patients who provide written consent to participate in this study from the patient or a surrogate (parent or legal guardian).
排除标准
- •(1)Patients who have participated in another clinical trial within 12 weeks prior to obtaining consent
- •(2)Patients who have taken sirolimus or everolimus within 52 weeks prior to enrollment
- •(3)Patients in whom neither the patient nor a surrogate can accurately record the number and duration of seizures
- •(4)Patients suspected of having progressive brain lesions on computed tomography(CT)or magnetic resonance imaging(MRI)performed to date
- •(5)Patients who have undergone neurosurgery for epilepsy(focal resection, cortical resection, functional hemispherectomy, corpus callosotomy, vagus nerve stimulation, or electrode implantation)within 26 weeks prior to enrollment
- •(6)Patients who are taking or have taken felbamate or vigabatrin within 26 weeks prior to enrollment
- •(7)Patients on a ketogenic diet
- •(8)Patients with previous suicide attempts
- •(9)Patients with a history or complications of substance abuse(including alcohol abuse)
- •(10)Patients of childbearing potential or male patients with a partner of childbearing potential who cannot agree to use contraception from the time of consent until 12 weeks after completion of study medication, patients who are pregnant or lactating, or patients who may be pregnant
- •(11)Patients with any of the following on clinical examination during the baseline observation period
- •Patients whose AST or ALT levels are 2.5 times or more than the reference value
- •Leukocytes count less than 3000 cells/mm3 or Ht less than 30%, platelets less than 80,000/mm3 or neutrophils less than 1000/mm3
- •HBs antigen-positive patients, HBs antibody-positive or HBc antibody-positive patients except after hepatitis B vaccination, or patients with active hepatitis C(HCV antibody-positive patients are excluded if they are inactive and have normal liver function values)
- •Patients with poorly controlled dyslipidemia, i.e., serum triglycerides >= 500 mg/dL or LDL cholesterol >= 190 mg/dL despite treatment for dyslipidemia
- •Patients with abnormal renal function. That is, estimated glomerular filtration rate(eGFR)less than 30 mL/min/1.73 m2
- •(12)Patients with concomitant arrhythmias requiring treatment
- •(13)Patients with concomitant cardiac or renal insufficiency that may affect hemodynamics
- •(14)Patients with concomitant immunodeficiency
- •(15)Patients with fever over 38 degree celsius or active infection
- •(16)Patients with interstitial pneumonia at the time of enrollment
- •(17)Patients who have undergone surgery(surgery requiring intracorporeal invasion or more than 3 stitches, including biopsy)within 12 weeks prior to enrollment.
- •(18)Patients who are judged to be inappropriate for this study by the investigator(s).
结局指标
主要结局
Relative reduction in the frequency of epileptic seizures
时间窗: 21 to 24 weeks after treatment
Relative reduction in the frequency of epileptic seizures from baseline (-4 to 0 weeks) for 21 to 24 weeks after treatment
次要结局
- Relative reduction in the number of epileptic seizures from baseline during each treatment period(excluding 21-24 weeks post-treatment)(each treatment period (excluding 21-24 weeks post-treatment))
- Relative reduction in the number of epileptic seizures from baseline from 1 to 24 weeks post-treatment(1 to 24 weeks post-treatment)
- Percent reduction from baseline in the number of epileptic seizures in each treatment period(each treatment period)
- Response rate from baseline in the number of epileptic seizures in each treatment period(each treatment period)
- Percentage of subjects lost without epileptic seizures in each treatment period(each treatment period)
- Change from baseline in total duration of cluster seizures(including superimposed seizures)such as epileptic spasms and myoclonic seizures in each treatment period(each treatment period)
- Percent relative decrease from baseline in the number of focal non-motor initiated seizures in each dosing period(continuous dosing period)(each dosing period (continuous dosing period))
- Number of epileptic seizures in each treatment period compared to baseline(each treatment period)
- Total duration of cluster seizures such as epileptic spasms and myoclonic seizures(including superimposed seizures)during each treatment period compared to baseline during each treatment period(each treatment period)
- Number of focal non-motor onset seizures in each treatment period compared to baseline(each treatment period)
研究者
相似试验
招募中
3 期
A phase III study (physician-initiated clinical trial) to evaluate the efficacy and safety of sirolimus for epileptic seizures with focal cortical dysplasia type IIFCDfocal cortical dysplasia type IIJPRN-jRCT2031230317Kato Mituhiro20
进行中（未招募）
不适用
Prelude A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin - NDEUCTR2005-004630-41-ITELI LILLY459
招募中
3 期
A Phase 3 clinical study to determine the pharmacokinetics, safety and efficacy of rVWF:rFVIII and rVWF in the treatment of bleeding episodes in subjects diagnosed with von Willebrand diseaseCoagulation disorderHereditary deficiency of Von Willebrand Factor in blood1006447710005330NL-OMON38008Baxter4
进行中（未招募）
不适用
Assessment of the efficacy of PGL4001 in repeated treatment courses on reducing symptoms of uterine fibroids causing heavy menstrual periodsterine myomas are benign, monoclonal, hormone-sensitive, smooth muscle tumours of the uterus. They are the most common tumour of the female reproductive tract in pre-menopausal women and mostly asymptomatic affecting approximately 40% of women between 35 and 55 years. When symptomatic, the main symptoms are heavy uterine bleeding, abdominal pressure, abdominal pain, increased urinary frequency and infertility.MedDRA version: 14.0Level: LLTClassification code 10046801Term: Uterine myomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-019497-32-PLPregLem S.A.200
进行中（未招募）
不适用
PGL4001 Efficacy Assessment in Reduction of symptoms due to uterine Leiomyomataterine myomas are benign, monoclonal, hormone-sensitive, smooth muscle tumours of the uterus. They are the most common tumour of the female reproductive tract in pre-menopausal women and mostly asymptomatic affecting approximately 40% of women between 35 and 55 years. When symptomatic, the main symptoms are heavy uterine bleeding, abdominal pressure, abdominal pain, increased urinary frequency and infertility.MedDRA version: 14.0Level: LLTClassification code 10046801Term: Uterine myomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-018999-25-ATPregLem S.A.200